CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)
Net loss	$ (7,936,864)	$ (5,531,360)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	550,682	502,540
Share-based payments for services	248,660	155,740
Equity based compensation	3,296,309	1,800,225
Common stock contributed to 401(k) plan	41,671	40,937
Gain on derivative instruments	(932,836)	(766,509)
Modification of warrants	192	0
(Increase)/decrease in assets:
Receivables	532,328	(28,278)
Prepaid expenses	(332,785)	86,567
Supplies used for R&D and manufacturing	0	(123,512)
Increase/(decrease) in liabilities:
Accounts payable	532,679	(393,064)
Accrued expenses	143,028	80,432
Due to employees	10,718	76,520
Other liabilities	18,319	(1,914)
Net cash used in operating activities	(3,827,899)	(4,101,676)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(3,149,820)	(101,820)
Proceeds from the sale of equipment	0	4,500
Expenditures for patent costs	0	(12,390)
Net cash used in investing activities	(3,149,820)	(109,710)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	13,559,500	5,050,003
Payments of stock issuance costs	(79,499)	(31,080)
Proceeds from the purchase of stock by officer	0	25,000
Proceeds from exercises of warrants and options	70,911	297,101
Payments on obligations under finance lease	(221,620)	(191,034)
Net cash provided by financing activities	13,329,292	5,149,990
NET INCREASE IN CASH AND CASH EQUIVALENTS	6,351,573	938,604
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	15,508,909	8,444,774
CASH AND CASH EQUIVALENTS, END OF PERIOD	21,860,482	9,383,378
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment included in current liabilities	1,700,969	296,941
Capitalizable patent costs included in current liabilities	15,000	0
Finance lease obligation included in accounts payable	1,752	745
Prepaid consulting services paid with issuance of common stock	243,687	(71,293)
Exercise of derivative liabilities	41,850	0
Financing costs included in current liabilities	88,021	76,650
Cash paid for interest	$ 277,618	$ 295,107